Senseonics (NYSE:SENS) Hits New 1-Year High – What’s Next?

Senseonics Holdings, Inc. (NYSE:SENS) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $1.20 and last traded at $1.06, with a volume of 18589708 shares. The stock had previously closed at $1.13.

Wall Street Analysts Forecast Growth

Several analysts recently commented on SENS shares. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Friday, November 15th. StockNews.com initiated coverage on shares of Senseonics in a research report on Thursday, December 26th. They set a “sell” rating for the company.

Senseonics Stock Performance

The business has a 50 day moving average price of $0.55 and a 200-day moving average price of $0.43. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Senseonics (NYSE:SENS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. The business had revenue of $4.26 million for the quarter, compared to the consensus estimate of $4.02 million. On average, equities research analysts forecast that Senseonics Holdings, Inc. will post -0.14 EPS for the current fiscal year.

Insider Activity

In other news, CEO Timothy T. Goodnow bought 315,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the acquisition, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, with a total value of $47,474.54. Following the purchase, the chief financial officer now directly owns 2,478,844 shares in the company, valued at $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

Several large investors have recently added to or reduced their stakes in SENS. Symmetry Partners LLC purchased a new stake in shares of Senseonics in the third quarter worth approximately $164,000. GSA Capital Partners LLP purchased a new stake in Senseonics in the 3rd quarter valued at $117,000. Geode Capital Management LLC boosted its holdings in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after acquiring an additional 179,103 shares during the last quarter. FMR LLC grew its stake in shares of Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after acquiring an additional 167,970 shares in the last quarter. Finally, Ridgecrest Wealth Partners LLC purchased a new stake in shares of Senseonics in the fourth quarter valued at about $60,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.